HPV INFECTION DURING ADOLESCENCE AND HPV VACCINATION

Öz

Human papilloma virus is commonly seen in sexually active adolescent girls. In most of the cases viral infection clears spontaneously within a limited time but persistent infection causes development of precancerous lesion or cancer around the female genitalia. Nowadays HPV vaccine is used to prevent unwanted dysplasia or cancer development throughout the gynecological tract. Our aim is to summarize the nature of the HPV infection especially in adolescence and take attention to HPV vaccines with the purpose of cancer prevention.

Anahtar Kelimeler

• Adolescent,HPV,Vaccination,Cervical Cancer

ADÖLESANLARDA HPV ENFEKSİYONU VE HPV AŞILARI

Öz

Human papilloma virus HPV enfeksiyonu özellikle cinsel aktif hayatın başlangıcındaki adölesanlarda oldukça yaygın olarak görülmektedir. Çoğu olguda spontan regresyon görülmesine rağmen persiste enfeksiyon varlığında takip eden yıllarda servikal, vaginal, vulvar ve anal bölgede prekanseröz lezyon ve sonrasında kanser oluşumuna yol açtığı bilinmektedir. Günümüzde HPV aşıları, HPV enfeksiyonuna bağlı istenmeyen etkilerin önlenmesi amacıyla kullanılmaktadır. Bu yazıda HPV enfeksiyonunun doğal süreci, adölesanlardaki seyri ve HPV aşıları hakkında genel bilgilerin verilmesi amaçlanmıştır.

Anahtar Kelimeler

• Adölesan,HPV,Aşılama,Servikal Kanser

Kaynakça

1. Grapsa D, Kairi-Vassilatou E, Kleanthis C, Dastamani C, Fillipidou A, Kondi-Pafiti A. Epithelial ovarian tumors in adolescents: a retrospective pathologic study and a critical review of the literature. J Pediatr Adolesc Gynecol 2011;24(6):386-8.
2. Michala L, Argyri E, Tsimplaki E, et al. Human Papilloma Virus infection in sexually active adolescent girls. Gynecol Oncol 2012;126(2):207-10.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9.
4. Monteiro DL, Sodre DC, Russomano FB, Trajano AJ, Silva KS. Incidence of genital warts in adolescents and their association with cervical intraepithelial lesions. Eur J Obstet Gynecol Reprod Biol 2013;168(1):80-2.
5. Schwarz TF, Huang LM, Medina DM, et al. Four- year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health 2012;50(2):187-94.
6. Massad LS, Einstein M, Myers E, Wheeler CM, Wentzensen N, Solomon D. The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecol Oncol 2009;114(2):360-4.
7. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338(7):423-8.
8. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med 2011;53 Suppl 1:S12-21.

9. Stanley M. Immune responses to human papillomavirus. Vaccine 2006;24 Suppl 1:S16-22.
10. Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991;83(14):997-1003.
11. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001;183(11):1554-64.
12. Thomas TL, Strickland O, Diclemente R, Higgins M. An opportunity for cancer prevention during preadolescence and adolescence: stopping human papillomavirus (HPV)-related cancer through HPV vaccination. J Adolesc Health 2013;52(5 Suppl):S60-8.
13. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6(5):271-8.
14. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus- like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367(9518):1247-55.
15. Harper DM, Paavonen J. Age for HPV vaccination. Vaccine 2008;26 Suppl 1:A7-11.
16. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007;38(3):189-97.
17. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364(9447):1757-65.
18. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347(21):1645-51.
19. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30 Suppl 5:F123-38.